Postcards from Bangalore
Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai,…
Menu
Made in China: Chidamide
Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China.…
Postcards from Trondheim
I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped…
The Life Sciences in Wyoming – Part Three of Three
In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part Two of this series, Dr. Lindemann highlights some of…
BIO Latin America Webinar: Comments and Perspectives
A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The…
Top 10 Drug Products in India
Do you know which are the top branded drug products in India? We didn't until we found this handy chart and article. We took their IMS data a step…
Indian Pharma Industry: Is the sun setting…or rising?
Much ink has already been spilled discussing the acquisition of Ranbaxy from Daiichi by Sun Pharma in an all stock transaction. A good analysis by a former Ranbaxy executive…
Indian Pharma Market Driven by Exports
Many people think of the BRIC countries as good domestic opportunities. But as this recent article points out, the Indian export market is growing rapidly. India's leading pharmaceutical…
FDA is right…and wrong
Today's issue of FiercePharma covered two interesting FDA decisions (or non- decisions, if you prefer). The first involves the FDA's decision not to approve generic versions of Purdue's Oxycontin:…
No incentive to Indian pharma to innovate
Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India's pharmaceutical companies should be focused on R&D of medicines that will help the people…